CMA reimposes excessive pricing fines on Pfizer and Flynn

The UK’s Competition and Markets Authority has collectively fined drugmakers Pfizer and Flynn Pharma nearly £70 million after an appellate court ordered it to reassess its original decision to punish the companies for excessively pricing a lifesaving anti-epilepsy drug.

Unlock unlimited access to all Global Competition Review content